Therapeutic radiopharmaceutical developer Algeta has inked an $800 million agreement with Bayer for the development and commercialization of its Alpharadin alpha-emitting pharmaceutical for treating bone metastases.
Based on radium-223, Alpharadin is currently being evaluated in a global, phase III trial in men with hormone-refractory prostate cancer that has spread to the bone. Algeta of Oslo, Norway, and Bayer of Leverkusen, Germany, will jointly develop Alpharadin, with Bayer contributing a substantial portion of the costs of future development and fully funding any additional late-stage trials.
Algeta will retain an option for copromotion and profit-sharing in the U.S. The firm will receive $61 million in cash upfront, followed by development, production, and commercialization milestones. It will be responsible for manufacturing and supplying Alpharadin.
Related Reading
Bayer to settle 'several' NSF contrast cases, April 17, 2009
Bayer partners with Hamamatsu, January 12, 2009
Bayer Schering, Epix to end Vasovist partnership, September 4, 2008
Bayer awarded Amerinet deal, April 14, 2008
New promise for therapeutic radiopharmaceuticals, June 2, 2006
Copyright © 2009 AuntMinnie.com
